Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Item

http://www.wikidata.org/entity/Q33402188

Q33402188

about

Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma Aurora Kinase Inhibitors: Current Status and Outlook Aurora-A Kinase as a Promising Therapeutic Target in Cancer Development of cell-cycle checkpoint therapy for solid tumors Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer Prognostic value of Aurora kinase A (AURKA) expression among solid tumor patients: a systematic review and meta-analysis Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis Inhibition of AURKA kinase activity suppresses collective invasion in a microfluidic cell culture platform Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.Aurora kinases: novel therapy targets in cancers Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation.The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers.Issues in interpreting the in vivo activity of Aurora-A Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy.Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models Function of AURKA protein kinase in the formation of vasculogenic mimicry in triple-negative breast cancer stem cells.A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.Cell cycle proteins as promising targets in cancer therapy Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.Mitosis as an anti-cancer drug target.Multispectral imaging: a review of its technical aspects and applications in anatomic pathology.MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.Characterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer.Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.Targeted delivery of silver nanoparticles and alisertib: in vitro and in vivo synergistic effect against glioblastoma.Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.Clinical Development of Anti-mitotic Drugs in Cancer.

P2860

Q24296639-E4F2559E-7D41-4248-9315-03C85933C50C Q26770583-520AF0AA-DD84-48DA-B69F-0CA735573116 Q26771371-F2B370FB-235A-4B17-801F-834C4B1A53F2 Q26781187-CB7BE7F4-4AFB-49E0-93EF-CB62145E9A85 Q26784060-B1B362C0-BF05-4E55-A68A-4578888ADD60 Q27024067-C1D87321-AA7A-4F8E-9565-5D1880B978D2 Q27347800-2B5EC710-953F-429E-8095-AB114E286B61 Q27853047-BB888298-44E2-4200-9177-B6F8E585D32F Q30855089-4FE800E9-7BA2-487C-B7D0-CF9E53B8D28F Q33410380-3C2F96AE-8485-4707-B406-A816E37592FD Q33412196-D1F8896F-0F97-4D2A-9125-2EB316CC8A32 Q33430055-A19796ED-8040-4F6A-A1ED-259F5825E04A Q33437992-0522834E-7314-4CA7-8309-29A5EA07C39B Q33618929-1EE7E0AF-3BF2-419A-8078-9E96F1E112A3 Q33917530-FCF22FF5-DF69-4111-A6A4-8007626BB887 Q34227665-60EFBD12-2E8A-4A16-90E6-73F0178D8D1B Q34498390-B1835A9E-43DC-4676-9FC1-C4281FE1CBB1 Q34623325-58DFF39C-34D5-49B8-BD76-871FC6A57E7D Q34964087-E2CBC829-61B9-41BC-ADCD-FACDD88D39B0 Q34977484-9D44A219-B8F4-47CF-8350-39673C03BBB0 Q35194626-BF9C2644-F1DB-48C8-908C-1F54CA263A95 Q36108892-7BF43283-6948-4CE6-836D-A35C1B7796AB Q36342896-6DA53C4D-C261-4B77-B580-69677138560D Q37020145-501DD3B9-7FAA-4CF9-84E1-7D4C3CFF0F40 Q37366202-40A25BC0-41BE-4C6D-9BC8-BD4D87A2674E Q37376481-9431F546-AA74-48DB-A482-178E180CF444 Q37553978-30013E21-B606-478B-9989-AA229149E7A2 Q37693690-6DE3EBF6-39D3-405D-811E-5CFFE0588F04 Q38099046-256CD4AA-ABB1-45BF-B0BA-91FB7FE21832 Q38115166-37B720A3-CE9A-4179-A678-98316A5C6586 Q38152999-E1B024C5-879F-4E0D-A1D6-6F8A413FE9A7 Q38260926-15F10999-2DC5-4F03-979B-6A58C5B6BEB9 Q38783162-6CA3BC89-74BF-45B2-A61A-2E6619EE831D Q38813996-11762695-BB98-4C6B-BA0F-390AC983970A Q38826254-2284BACF-729F-4AA3-A989-3A2949898DC2 Q38894287-4D08061B-1ACC-41FB-9EBF-529ECDAAFAF9 Q39028389-8D9774BC-D23C-4A21-A986-97686087C02C Q39033903-CF5EDCF0-E227-4E4E-8508-6BAA234CF10D Q39115623-7BEF58BE-E52B-4AEC-A207-24B22563C03C Q39363642-0ABE854D-D432-4436-B44D-74DADD44ABEF

P2860

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Item

http://www.wikidata.org/entity/Q33402188

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu